FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

MLA

Amna Ibrahim, et al. “FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 22, no. 18, Mar. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....60bb75da788f963503b1cc74ee72274e&authtype=sso&custid=ns315887.

APA

Amna Ibrahim, Xavier Ysern, Geoffrey Kim, Todd R. Palmby, Amy E. McKee, Xiao Hong Chen, Sarah E. Dorff, Julia A. Beaver, Qi Liu, Joyce Cheng, Yaning Wang, Richard Pazdur, Jeannette Dinin, Gwynn Ison, Ge Bai, Shenghui Tang, William F. Pierce, Rajeshwari Sridhara, Anshu Marathe, … W. David McGuinn. (2016). FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(18).

Chicago

Amna Ibrahim, Xavier Ysern, Geoffrey Kim, Todd R. Palmby, Amy E. McKee, Xiao Hong Chen, Sarah E. Dorff, et al. 2016. “FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 22 (18). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....60bb75da788f963503b1cc74ee72274e&authtype=sso&custid=ns315887.